CT indicates computed tomographic; FH, family history; PP, postpolypectomy; FOBT, fecal occult blood test–positive.
Regge D, Laudi C, Galatola G, Della Monica P, Bonelli L, Angelelli G, Asnaghi R, Barbaro B, Bartolozzi C, Bielen D, Boni L, Borghi C, Bruzzi P, Cassinis MC, Galia M, Gallo TM, Grasso A, Hassan C, Laghi A, Martina MC, Neri E, Senore C, Simonetti G, Venturini S, Gandini G. Diagnostic Accuracy of Computed Tomographic Colonography for the Detection of Advanced Neoplasia in Individuals at Increased Risk of Colorectal Cancer. JAMA. 2009;301(23):2453–2461. doi:10.1001/jama.2009.832
Author Affiliations: Radiology Unit (Drs Regge, Della Monica, and Gallo) and Gastroenterology Unit (Drs Laudi and Galatola), Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; Epidemiology Unit (Drs Bonelli, Boni, and Bruzzi) and Radiology Unit (Dr Grasso), National Institute for Cancer Research, Genoa, Italy; Radiology Department, University of Bari, Policlinico Hospital, Bari, Italy (Dr Angelelli); Radiology Unit, Salvatore Maugeri IRCCS Foundation, Veruno, Novara, Italy (Dr Asnaghi); Radiology Department, University Cattolica, Policlinico Agostino Gemelli, Rome, Italy (Dr Barbaro); Radiology Department, University of Pisa, Pisa, Italy (Drs Bartolozzi and Neri); Radiology Department, University of Leuven, UZ Gasthuisberg, Leuven, Belgium (Dr Bielen); Radiology Unit, Valduce Hospital, Como, Italy (Dr Borghi); Radiology Department, University of Turin, San Giovanni Battista Hospital, Turin (Drs Cassinis, Martina, and Gandini); Radiology Department, University of Palermo, Policlinico Paolo Giaccone, Palermo, Italy (Dr Galia); Gastroenterology Unit, Nuovo Regina Margherita Hospital, Rome (Dr Hassan); Radiology Department, University La Sapienza, Polo Didattico Pontino ICOT, Rome (Dr Laghi); CPO Piemonte, ASO San Giovanni Battista, Turin (Dr Senore); Radiology Department, Tor Vergata University, Rome (Dr Simonetti); and Radiology Unit, National Cancer Institute, Aviano, Pordenone, Italy (Dr Venturini).
Context Computed tomographic (CT) colonography has been recognized as an alternative for colorectal cancer (CRC) screening in average-risk individuals, but less information is available on its performance in individuals at increased risk of CRC.
Objective To assess the accuracy of CT colonography in detecting advanced colorectal neoplasia in asymptomatic individuals at increased risk of CRC using unblinded colonoscopy as the reference standard.
Design, Setting, and Participants This was a multicenter, cross-sectional study. Individuals at increased risk of CRC due to either family history of advanced neoplasia in first-degree relatives, personal history of colorectal adenomas, or positive results from fecal occult blood tests (FOBTs) were recruited in 11 Italian centers and 1 Belgian center between December 2004 and May 2007. Each participant underwent CT colonography followed by colonoscopy on the same day.
Main Outcome Measures Sensitivity and specificity of CT colonography in detecting individuals with advanced neoplasia (ie, advanced adenoma or CRC) 6 mm or larger.
Results Of 1103 participants, 937 were included in the final analysis: 373 cases in the family-history group, 343 in the group with personal history of adenomas, and 221 in the FOBT-positive group. Overall, CT colonography identified 151 of 177 participants with advanced neoplasia 6 mm or larger (sensitivity, 85.3%; 95% confidence interval [CI], 79.0%-90.0%) and correctly classified results as negative for 667 of 760 participants without such lesions (specificity, 87.8%; 95% CI, 85.2%-90.0%). The positive and negative predictive values were 61.9% (95% CI, 55.4%-68.0%) and 96.3% (95% CI, 94.6%-97.5%), respectively; after group stratification, a significantly lower negative predictive value was found for the FOBT-positive group (84.9%; 95% CI, 76.2%-91.3%; P < .001).
Conclusions In a group of persons at increased risk for CRC, CT colonography compared with colonoscopy resulted in a negative predictive value of 96.3% overall. When limited to FOBT-positive persons, the negative predictive value was 84.9%.
Colorectal cancer (CRC) accounts for approximately 210 000 deaths each year in Europe.1 The majority of CRCs arise within adenomatous polyps,2 and polypectomy is associated with a reduction in CRC incidence and mortality.3 The target lesions in mass screening programs are advanced adenomas, which harbor the greatest cancer risk, and early stage CRC,4 but adherence to screening procedures remains suboptimal.5,6
Computed tomographic (CT) colonography has been shown to be sufficiently accurate in detecting colorectal neoplasia.7,8 Less invasive and better tolerated than colonoscopy,9,10 CT colonography is now considered a valid alternative for CRC screening in the general population.11
Individuals with first-degree family history of advanced colorectal neoplasia, those who have had resection of colorectal adenomas, and those with positive results from fecal occult blood tests (FOBTs) are at increased risk of CRC. However, adherence to follow-up colonoscopy in these individuals is suboptimal.12- 14 Being less invasive and thus more tolerable, CT colonography may increase acceptability and adherence to screening, but little information is available on its performance.
The aim of our study was to assess sensitivity and specificity of CT colonography in detecting advanced neoplasia (ie, advanced adenoma or CRC) 6 mm or larger in individuals at increased risk of developing CRC, because of either family history of advanced colorectal neoplasia in first-degree relatives, personal history of adenomas, or positive results from immunochemical FOBTs.
In this multicenter cross-sectional study, each participant underwent CT colonography followed by colonoscopy on the same day. Both tests were carried out in the same center.
Individuals were eligible for inclusion into the study if they met 1 of 3 categories. Group 1 comprised first-degree relatives of patients with advanced colorectal neoplasia diagnosed before the age of 60 years and were aged 40 to 65 years (family-history group). Group 2 individuals entered a colonoscopy surveillance program after endoscopic removal of colorectal adenomas15 and were aged 18 to 70 years (postpolypectomy group). Group 3 comprised individuals with positive results from FOBTs who were aged 59 to 69 years and participating in a CRC screening program (FOBT-positive group).
Individuals were excluded if they had any of the following: clinical diagnosis of familial adenomatous polyposis or hereditary nonpolyposis CRC,16 normal colonoscopy or sigmoidoscopy performed within the last 3 years, diagnosis of cancer at any site at the time of selection, severe comorbidity limiting life expectancy, inflammatory bowel disease, celiac disease, autoimmune disease, symptoms or signs that clinically warranted colon imaging, evidence of increased risk of being harmed by undergoing colonoscopy as judged by the endoscopist, psychological or physical conditions that contraindicated colonoscopy, anticoagulant therapy, or pregnancy at time of study inclusion or CT colonography.
Participating centers were required to have the following 4 facilities: a radiology unit equipped with at least one 4-slice CT scanner, where at least 1 radiologist had reported 50 or more CT colonography procedures under supervision of an expert; a digestive endoscopy unit with state-of-the-art video endoscopy and endoscopists who had performed at least 500 colonoscopies and 100 polypectomies; a general surgery unit; and a pathology unit with a pathologist experienced in evaluating colorectal diseases. The centers also needed the resources to perform at least 50 extra CT colonography procedures and 50 extra colonoscopies yearly in addition to their routine workloads. Following a start-up visit by investigators from the coordinating center, 21 centers (20 in Italy, 1 in Belgium) were approved to join the study; each center was required to enroll at least 1 participant per month. An institutional review board including all participating centers agreed on the study protocol, which was then approved by each center's ethical committee.
Eligible participants were prospectively selected in each center by a study investigator in 3 ways. Relatives of patients with advanced neoplasia were recruited into the family-history group (group 1) after interviews with all patients referred for surgery or endoscopic polypectomy because of histologically proven advanced colorectal neoplasia diagnosed before the age of 60 years; their first-degree relatives aged 40 to 65 years were identified and permission obtained to contact them. Participants were identified for groups 2 and 3 by interviewing all individuals without personal history of colorectal neoplasia who attended the gastroenterology units involved in the study and by periodically checking indications for colonoscopy reported in the endoscopy waiting list.
All eligible participants were contacted, interviewed, and offered participation in the study. Individuals who accepted were prospectively registered and booked for same-day and same-center CT colonography and colonoscopy. Written informed consent was obtained from each participant. A dedicated password-protected database was designed and managed on a secure server by the Clinical Trials Core Facility of the National Institute for Cancer Research, Genoa, Italy (http://clinicaltrials.istge.it/ist/rde).
Full bowel purgation was required because participants had to undergo colonoscopy on the same day as CT colonography. No specific colon cleansing directions were given to the participating centers, but internationally recognized quality standards had to be met.17 Hydrosoluble iodine agents alone or in combination with barium sulfate were accepted for oral tagging.7,18
Each participant was placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously according to common practice in the participating centers. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide; this was performed either manually using a balloon pump or with an automatic device until maximum tolerance was reached. Computed tomographic colonography was performed with the participant in the supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 2.5 mm. Intravenous contrast medium was not administered. Duration of CT colonography, reporting time, and adverse events were recorded.
On completion of the CT scan, 1 radiologist interpreted the CT colonography on his or her own workstation using either 2-dimensional or 3-dimensional primary reading according to preference. Lesions were assigned to 1 of the following bowel segments: cecum, ascending colon including the hepatic flexure, transverse colon including the splenic flexure, descending colon, sigmoid colon, and rectum. Lesion size was reported as the measurement of its largest diameter (the stalk of the polyp when visible was not considered for measurement) on 2-dimensional reformatted images, using a standard window setting of 1500 Hounsfield units. The results of the CT colonography interpretation were recorded on different pages, one for each of the 6 bowel segments, and put separately into sealed envelopes that were delivered to the endoscopy unit where colonoscopy was scheduled. Because of the low specificity of CT colonography for small lesions, polyps smaller than 6 mm were recorded but not registered in the envelopes delivered to the endoscopy unit.19
Colonoscopy was performed at least 3 hours after CT colonography. Sedation was carried out according to the common clinical practice of each participating center.
The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a polyp measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy.20 The duration of colonoscopy and any adverse events were recorded.
Radiologists and endoscopists were required to evaluate the adequacy of preparation for each segment of the bowel. Global examination quality was considered optimal when distension and visualization of the bowel wall were excellent; good when part of the bowel wall was not visualized due to luminal collapse, fluid, or stool (however, still allowing detection of lesions ≥10 mm); and poor when examination quality could not guarantee visualization of large lesions.21 The main reasons for incomplete visualization (fecal and/or liquid residue or collapsed segment) were recorded.
According to the adopted segmental checking procedure, a lesion found at CT colonography was matched to a corresponding one found at colonoscopy when it was located in the same or adjacent colon segment and when its size differed by no more than 50%.7 Matching was performed immediately after conclusion of both tests, if necessary by reviewing colonoscopy video registration and CT colonography images. This algorithm was used only for the “per-polyp” analysis.
Lesion size was measured at endoscopy using open biopsy forceps. All visible lesions were removed; those retrieved were sent for local pathologist evaluation and classified according to criteria from the World Health Organization.22 Adenomas were considered advanced when 10 mm or larger, if they had a 20% or more villous component, or if they had high-grade dysplasia; all the others were considered low-risk adenomas.
The reference standard for lesion diagnosis was the result of the unblinded colonoscopy (ie, all polyps ≥6 mm detected at colonoscopy before and after segmental unblinding of CT colonography) and the histological evaluation of the removed polyps. Reasons for exclusion from the analyses were indicated in the research protocol as follows: cases entered by a center that enrolled fewer than 1 participant per month during the study period, participants who withdrew their consent before testing or refused to undergo CT colonography or colonoscopy, incomplete colonoscopy with a negative test result up to the examined point, or histology of the largest lesion not being available. Participants with a complete CT colonography and a diagnostic colonoscopy, including those interrupted due to obstruction, were considered for analysis.
End Points. The primary end point of the study was CT colonography performance as a screening test using unblinded colonoscopy as the reference standard. The analysis was performed according to a per-patient evaluation.
Participants were considered as having a positive result at the reference standard when at least 1 advanced neoplasia 6 mm or larger was found at the reference standard. When 2 or more lesions were removed in the same patient, the one with the worst histology was classified as the index lesion; for multiple lesions with the same histology, the largest one was considered. Participants without colorectal lesions, those with nonadenomatous lesions, those with nonadvanced adenomas, and those with advanced adenomas smaller than 6 mm were classified as having negative results.
Computed tomographic colonography was reported to be positive when at least 1 lesion 6 mm or larger was detected; otherwise, it was reported as negative. If CT colonography was positive and the index lesion was an advanced neoplasia 6 mm or larger, the CT colonography result was considered to a true positive. If CT colonography was positive but the case was classified as negative at the reference standard, the CT colonography result was considered a false positive. Computed tomographic colonography sensitivity, specificity, positive predictive value, and negative predictive value, along with their relative 95% confidence intervals (CIs), were calculated cumulatively and according to study group.
Secondary End Points. Per-patient sensitivity, specificity, and positive and negative predictive values were calculated also for advanced neoplasia 10 mm or larger. For this purpose, if the CT colonography result was positive and the index lesion was an advanced neoplasia 10 mm or larger, the CT colonography result was considered a true positive for a lesion in that size class. If the CT colonography result was positive but no advanced neoplasia 10 mm or larger was found at unblinded colonoscopy, the CT colonography result was considered a false positive for a lesion in that size range. Per-polyp sensitivity was calculated as the percentage of positive CT colonography matching findings among all advanced neoplasia sized in the range of interest that were detected at unblinded colonoscopy, using the matching algorithm described before.
The χ2 test was used to assess statistical significance of differences among proportions. All P values involved hypothesis tests against a 2-sided alternative and were considered significant when P < .05. The analyses were performed using SAS release 9.1 (SAS Institute, Cary, North Carolina).
Sample Size Estimate. We assumed that CT colonography could be proposed as a screening test if its sensitivity was 70% or greater. Assuming that 150 participants had advanced lesions found at colonoscopy, the precision of the estimates would be approximately ±7% for CT colonography sensitivity between 80% and 90%. Thus, under a conservative assumption that CT colonography sensitivity for advanced lesions was greater than 80%, the study had greater than 90% power of rejecting the hypothesis at .05 (1-sided level of significance) that CT colonography true sensitivity was 70% or less. The projected prevalence of advanced lesions in the study population ranged from 4% to 15% depending on the relative contribution of the 3 study groups. Accordingly, it was estimated that no fewer than 1000 participants would have had to be enrolled for the study to have sufficient statistical power and that recruitment had to be continued until 150 participants with advanced neoplasia had been found at unblinded colonoscopy.
Between December 2004 and May 2007, 1103 participants were enrolled in 17 centers. Recruitment varied between 1 and 291 participants per center. Of the enrolled participants, 937 participants (85.0%) from 12 centers (11 in Italy, 1 in Belgium) were included in the analysis (Figure). Of those 937 participants, 373 (39.8%) were in the family-history group, 343 (36.6%) in the postpolypectomy group, and 221 (23.6%) in the FOBT-positive group; the prevalence of advanced neoplasia was 7.5%, 11.1%, and 50.2%, respectively (P < .001). Participant characteristics and size and histology of the colorectal findings are reported in Table 1.
Technical details of the CT colonography examination are in Table 2. There were no clinically significant complications after CT colonography. The median time spent by participants in the CT suite (available for 658 participants) was 15 minutes (range, 10-50 minutes). The median time required for interpretation of the CT colonography studies was 18 minutes (range, 3-55 minutes); time spent was shorter for primary 2-dimensional assessment (17 minutes; range, 3-55 minutes) than for primary 3-dimensional assessment (20 minutes; range, 5-55 minutes; P < .001).
Global examination quality was reported for 863 participants. It was optimal in 533 participants (61.8%), good in 282 (32.7%), and poor in 48 (5.6%). The main reasons for poor-quality examinations were fecal residue in 33 participants (3.8%), liquid residue in 5 (0.6%), and bowel collapse in 5 (0.6%); the reason for poor global examination quality was not recorded in 5 cases (0.6%).
The CT colonography sensitivity, specificity, and positive and negative predictive values to detect a participant with at least 1 advanced neoplasia 6 mm or larger were 85.3% (95% CI, 79.0%-90.0%), 87.8% (95% CI, 85.2%-90.0%), 61.9% (95% CI, 55.4%-68.0%), and 96.3% (95% CI, 94.6%-97.5%), respectively.
Considering only disease-positive participants with advanced neoplasia 10 mm or larger, CT colonography identified 119 of 131 participants with at least 1 such lesion (sensitivity, 90.8%; 95% CI, 84.2%-95.0%) and 681 of 806 participants without (specificity, 84.5%; 95% CI, 81.8%-86.9%); the corresponding positive and negative predictive values were 48.8% (95% CI, 42.3%-55.2%) and 98.3% (95% CI, 97.0%-99.1%), respectively. Sensitivity for participants with cancer was 95.1% (95% CI, 83.5%-99.4%); CT colonography detected 39 of 41 participants with cancer, including all 3 with diameters of 6 to 9 mm. The diagnostic performance of CT colonography in detecting participants with at least 1 advanced neoplasia 6 mm or larger according to the risk group is in Table 3. When comparing CT colonography performance in the 3 different groups of participants, sensitivity for advanced neoplasia 6 mm or larger was similar. On the other hand, specificity was significantly higher in the family-history and postpolypectomy groups as compared with the FOBT-positive group (93.6% and 85.3% vs 76.4%, respectively; P < .001).
Positive predictive value varied between 41.6% in the postpolypectomy group and 78.7% in the FOBT-positive group (P < .001), and the negative predictive value ranged between 84.9% in the FOBT-positive group and 98.5% in the family-history group (P < .001). The test-positive rate in the family-history, postpolypectomy, and FOBT-positive groups was 12.1%, 22.4%, and 55.2%, respectively.
Table 4 lists results of the retrospective analysis performed by 2 experienced radiologists on the 93 cases that were negative at colonoscopy and classified as positive at CT colonography. The false-positive rate varied from 6.4% in the family-history group to 23.6% in the FOBT-positive group. The main reasons for erroneous CT interpretation were presence of nonadvanced neoplasia in polyps 6 mm or larger (n = 42; 5.5%) and perception errors (n = 17; 2.2%).
A total of 375 lesions 6 mm or larger were detected in 235 participants. Histology and size of the 347 endoscopically retrieved lesions are reported in Table 5 according to their bowel location. Sensitivity according to the per-polyp analysis is listed in Table 6. Blinded colonoscopy missed 2 advanced adenomas: a 13-mm pedunculated polyp in the cecum and an 18-mm flat lesion in the ascending colon. Two participants were hospitalized for bleeding after polypectomy.
The overall per-patient sensitivity for CT colonography detecting advanced neoplasia 6 mm or larger and 10 mm or larger was 85.3% and 90.8%, respectively, which are comparable with figures reported in 2 large trials on average-risk individuals7,8 but higher than those of 2 previous multicenter studies that included patients with clinical indication for colonoscopy or those with family history of CRC.23,24 Computed tomographic colonography can only classify a lesion by its size. Thus, large hyperplastic polyps or large low-risk adenomas can generate false-positive findings on CT colonography when considering as positive only patients with advanced neoplasia 6 mm or larger, as we did in our study. This may lead to a possible reduction of CT colonography specificity. In our survey, the index lesion was a low-risk adenoma or a nonadenomatous lesion in 28 and 27 participants, respectively, thus accounting for only 5.9% of the participants. Therefore, our specificity was similar to that of other studies primarily aimed at detecting adenomas 6 mm or larger independently of their histology.7,8
Computed tomographic colonography was performed safely: no serious adverse events were recorded. Furthermore, to minimize radiation-induced cancer risk, we adopted a low-dose protocol that did not negatively affect CT colonography performance.25 Our study also provided the opportunity to assess CT colonography performance in 3 different groups of asymptomatic individuals at increased risk of carrying advanced colorectal neoplasia. This allowed us to draw important practical implications.
The prevalence of advanced neoplasia in our participants with family history of advanced colorectal neoplasia was 7.5%, which is similar to the figures reported elsewhere.12,26 Our values of a 12% test-positive rate, 51% positive predictive value, and 82% sensitivity suggest a potentially effective use of CT colonography as an alternative to colonoscopy for screening individuals with family history of advanced colorectal neoplasia. Computed tomographic colonography has been shown to be better accepted than colonoscopy27 and has a negligible risk of serious adverse events; thus, it may help increase the low adherence reported for individuals who are candidates for screening,12 which is the main negative factor affecting its efficacy in reducing mortality from CRC.
Surveillance colonoscopy following polypectomy accounts for approximately one-fourth of all endoscopic procedures,28 but the yield in terms of polypectomy rate is very low despite this workload. In our postpolypectomy group, the prevalence of advanced neoplasia was 11%, in line with the available literature.29 Lower figures are observed in patients without high-risk adenomas at the index colonoscopy, but our protocol did not stratify participants according to this information. According to our results, 16% of advanced adenomas developing during postpolypectomy follow-up would have not been detected by CT colonography. However, this negative aspect must be weighed against the higher drop-out rate reported during colonoscopy follow-up of postpolypectomy patients.13 Here again, the better acceptance27 and lower invasiveness of CT colonography might reduce this drop-out rate, thus making it an effective test for increasing in absolute terms the protective effect of postpolypectomy follow-up toward the development of CRC. This strategy may be most useful in patients whose index lesion is a low-risk adenoma, thus reducing the workload of endoscopy units while still ensuring an efficient detection rate of clinically relevant lesions.
The prevalence of advanced colorectal neoplasia in our participants with positive FOBT results was 50%, which is also in line with the reported literature.30 Despite this evidence, nonadherence to post-FOBT colonoscopy has been shown to occur in up to one-third of cases.14 This would obviously reduce the efficacy of mass screening using FOBT. Our results do not support using CT colonography as a first-line strategy in FOBT-positive subjects. Because of the high prevalence of advanced neoplasia in this group of participants, colonoscopy would have been performed in 55% of the cases if CT colonography had been used as a screening test, making such a strategy not as cost-effective as using colonoscopy as a first-line screening test. This statement is also supported by the low specificity (76%) in our FOBT-positive participants, because of the higher rate of nonadenomatous lesions and low-risk adenomas detected at CT colonography and the high rate of observer errors in this group. Errors may be explained by radiologists not being blinded to the participant's group; the awareness of an expected high prevalence of disease in FOBT-positive participants might increase false-positive reporting, thus generating useless referral to colonoscopy. Nevertheless, the high accuracy of CT colonography for cancer in our study is a valid argument for its use in FOBT-positive patients who refuse colonoscopy.
There were 3 limitations to the study. The first limitation is that, because this was a multicenter study, CT colonography protocols and radiologist experience were probably not uniform across participating centers; it has not been assessed how results could have been affected by differences in colon preparation, scanning protocol, and interpretation paradigm. However, this study was designed while bearing in mind how CT colonography is typically performed in daily clinical practice. To further improve test performance, CT colonography technique should be standardized internationally and adequate training strategies implemented.
A second limitation of our study was the variable working conditions between centers and the variable motivations of the radiologist, and this limitation may have adversely affected CT colonography performance. Most radiology units have heavy clinical workloads, and our protocol imposed on the radiologist a 3-hour time limit for reporting CT colonography results to the endoscopy suite while still handling ongoing routine clinical work. Both of these stress factors create nonideal conditions in a screening setting. Furthermore, the time it took to interpret CT colonography results was lengthy and might not be cost-effective in mass screening programs. Also, the prior knowledge that their reports would be checked against those of the subsequent colonoscopy findings might have caused radiologists to take more time in an effort to be more accurate. Computer-aided diagnosis and reporting in a protected environment might help increase accuracy of CT colonography screening and reduce reporting time. A third limitation is that colonoscopy was used as the reference standard; colonoscopy itself may miss some lesions and longer-term follow-up is needed to determine whether clinically significant lesions were missed.
In summary, in a group of persons at increased risk of CRC, CT colonography compared with colonoscopy resulted in a negative predictive value of 96.3% and a positive predictive value of 61.9% overall. When limited to FOBT-positive persons, the negative predictive value was 84.9%.
Corresponding Author: Cristiana Laudi, MD, Gastroenterology Unit, Institute for Cancer Research and Treatment, Strada Provinciale 142, km 3.95, 10060 Candiolo, Turin, Italy (email@example.com).
Author Contributions: Dr Regge had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Regge, Galatola, Bonelli, Bruzzi, Senore, Gandini.
Acquisition of data: Regge, Laudi, Galatola, Angelelli, Asnaghi, Barbaro, Bartolozzi, Bielen, Boni, Borghi, Cassinis, Galia, Gallo, Grasso, Laghi, Martina, Neri, Simonetti, Venturini, Gandini.
Analysis and interpretation of data: Regge, Laudi, Galatola, Della Monica, Bonelli, Barbaro, Bartolozzi, Boni, Bruzzi, Hassan, Neri, Simonetti, Venturini, Gandini.
Drafting of the manuscript: Regge, Laudi, Galatola, Della Monica, Bonelli, Angelelli, Boni, Borghi, Bruzzi, Galia, Gallo, Senore, Simonetti, Venturini.
Critical revision of the manuscript for important intellectual content: Regge, Laudi, Galatola, Asnaghi, Barbaro, Bartolozzi, Bielen, Boni, Cassinis, Grasso, Hassan, Laghi, Martina, Neri, Gandini.
Statistical analysis: Laudi, Della Monica, Bonelli, Boni, Bruzzi.
Obtained funding: Regge.
Administrative, technical, or material support: Regge, Barbaro, Bartolozzi, Borghi, Grasso, Simonetti, Venturini, Gandini.
Study supervision: Laudi, Galatola, Barbaro, Hassan, Gandini.
Financial Disclosures: None reported.
Funding/Support: This study was funded by a grant from the AIRC (Italian Association for Cancer Research) for 2005 through 2007, a grant for Progetti di Ricerca Finalizzata from Regione Piemonte, the Fondazione Cassa di Risparmio di Torino, and the Compagnia di San Paolo. The study was also endorsed by the Italian Society of Medical Radiology (SIRM) and the Italian Society of Gastroenterology (SIGE).
Role of the Sponsor: The funding organizations had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: The following individuals collaborated on the acquisition of the data: Carlo Neumaier, MD; Jessica Bianucci, MD, Radiology Unit, and Emanuele Meroni, MD; Alberto Fasoli, MD, Endoscopy Unit, National Institute for Cancer Research, Genoa, Italy; Andrea Ferraris, MD, Radiology Department, and Giorgio Saracco, MD; Mario Rizzetto, MD; Gastroenterology Department, University of Turin, San Giovanni Battista Hospital, Turin, Italy; Francesca Cerri, MD, Radiology Department, University of Pisa, Italy; Pietro Occhipinti, MD; Silvia Saettone, MD, Gastroenterology Unit, SS Trinità Hospital, Borgomanero, Novara, Italy; Sandro Morassut, MD; Luca Ballestreri, MD, Radiology Unit, and Renato Cannizzaro, MD; Mara Fornasarig, MD, Gastroenterology Unit, National Cancer Institute, Aviano, Pordenone, Italy; Amato Antonio Stabile Ianora, MD; Pasquale Pedote, MD, Radiology Department, and Giuseppe Carbotta, MD; Onofrio Caputi, MD, Surgery Department, University of Bari, Policlinico Hospital, Bari, Italy; Alberto Martegani, MD, Radiology Unit, and Giorgio Minoli, MD; Giancarlo Spinzi, MD, Gastroenterology Unit, Valduce Hospital, Como, Italy; Roberto Fiori, MD, Radiology Department, Tor Vergata University, Rome, Italy; Lorenzo Bonomo, MD; Carmen Tebala, MD, Radiology Department; Maria Elena Riccioni, MD, Surgical Endoscopy Department; and Claudio Coco, MD, Surgery Department, University Cattolica, Policlinico Agostino Gemelli, Rome; Massimo Midiri, MD; Giuseppe Lo Re, MD, Radiology Department, and Francesco D’Arpa, MD; Rita Machì, MD, Endoscopy Department, University of Palermo, Policlinico Paolo Giaccone, Palermo, Italy; and Paul Rutgeerts, MD, Gastroenterology Department, University of Leuven, UZ Gasthuisberg, Leuven, Belgium. Nereo Segnan, MD, CPO Piemonte, ASO San Giovanni Battista, Turin, collaborated on the design of the study. None of these individuals received compensation for their contributions beyond their salaries.